Integra Lifesciences stock analysis
Integra Lifesciences (IL3) Stock Price & Analysis
IL3 Stock Chart & Stats
- Day’s Range
- EUR 12.60 - EUR 12.60
- 52-Week Range
- EUR 7.60 - EUR 17.30
- Previous Close
- EUR 12.50
- Volume
- N/A
- Average Volume (3M)
- 7
- Market Cap
- EUR 1.02B
- Enterprise Value
- EUR 2.97B
- Total Cash (Recent Filing)
- EUR 311.93M
- Total Debt (Recent Filing)
- EUR 2.00B
- Price to Earnings (P/E)
- 88.0
- Beta
- 0.97
- Next Earnings
- Mar 03, 2027 (Est.)
- EPS Estimate
- 0.58
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Neurosurgery Growth
Neurosurgery growth across multiple products indicates broad demand rather than reliance on a single offering. Continued adoption in a specialized clinical market can support recurring procedure-linked revenue and reinforce Integra’s position with hospitals and surgeons over the next several quarters.
Strong Cash Generation
Record operating and free cash flow improves Integra’s ability to fund operations, service debt and invest in commercial initiatives without relying entirely on external capital. If sustained, stronger cash conversion can gradually improve financial resilience and support execution.
Refinancing Flexibility
Extending maturities and adding covenant capacity reduces near-term refinancing pressure and gives management more time to execute its operational recovery. This does not remove leverage, but it can provide a more stable funding framework for product launches and growth investments.
Bears Say
Elevated Leverage
The materially higher leverage burden leaves less flexibility to absorb operating setbacks, fund expansion or pursue acquisitions. It also increases the importance of reliable cash generation, while weaker recent returns and profitability make balance-sheet improvement more difficult.
Cincinnati Disruption
The prolonged Cincinnati disruption extends beyond a single quarter and is expected to affect early 2027 revenue, gross profit and customer retention. Limited back-order recovery assumptions indicate that some demand may shift to competitors, creating a lasting execution and share-recapture challenge.
Volatile Profitability
Large swings in earnings and recent near-breakeven profitability reduce confidence in the durability of Integra’s earnings power. Inconsistent operating results can constrain internal investment, complicate debt reduction and make future performance more sensitive to execution and product mix.
Integra Lifesciences News
IL3 FAQ
What was Integra Lifesciences’s price range in the past 12 months?
What is Integra Lifesciences’s market cap?
When is Integra Lifesciences’s upcoming earnings report date?
How were Integra Lifesciences’s earnings last quarter?
Is Integra Lifesciences overvalued?
Does Integra Lifesciences pay dividends?
What is Integra Lifesciences’s EPS estimate?
How many shares outstanding does Integra Lifesciences have?
What happened to Integra Lifesciences’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Integra Lifesciences?
What is the TipRanks Smart Score and how is it calculated?
Integra Lifesciences Stock Smart Score
Company Description
Integra Lifesciences
Integra LifeSciences Holdings Corporation is a medical technology company focused on the creation, production, and global distribution of advanced surgical implants and instruments. These products are utilized across various medical fields, including neurosurgery, limb reconstruction, and general surgical procedures. The company operates through two primary business segments: Codman Specialty Surgical and Tissue Technologies. The Codman Specialty Surgical division offers a comprehensive range of neurosurgical and neuro-critical care products. This includes specialized equipment for tissue ablation, dural repair solutions, cerebral spinal fluid management systems, intracranial monitoring tools, and cranial stabilization devices. Additionally, this segment provides surgical headlamps, various instrumentation, and supports these offerings with asset management software, technical assistance, and after-market services. Integra also supplies an extensive catalog of approximately 40,000 surgical instrument designs, along with a wide selection of surgical and lighting products. Its clientele spans hospitals, surgical centers, and extends to dental, podiatry, and veterinary practices. The Tissue Technologies segment specializes in innovative regenerative technology products for the treatment of both acute and chronic wounds. It further provides surgical tissue repair solutions for a multitude of applications, such as hernia repair, peripheral nerve protection and regeneration, and tendon reconstruction. This encompasses a broad array of offerings for skin and wound repair, plastic and reconstructive surgery products, bone grafting materials, and specialized nerve and tendon repair products. Integra LifeSciences distributes its diverse product portfolio internationally, reaching markets throughout the United States, Europe, Asia Pacific, and other global regions. Distribution is managed directly through its dedicated sales forces and various other channels, serving a wide array of healthcare entities including hospitals, integrated health networks, group purchasing organizations, individual clinicians, surgery centers, and other healthcare providers. Founded in 1989, Integra LifeSciences Holdings Corporation is headquartered in Princeton, New Jersey.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Stuart Essig
- Employees
- 4,427
- Website
- www.integralife.com
- Address
- 1100 Campus Road, Princeton, NJ, 08540, US
Integra Lifesciences (IL3) Earnings & Revenues
IL3 Company Deck
IL3 Earnings Call
Earnings Call SentimentNeutral
The call presented meaningful operational and financial progress, including record quarterly operating cash flow, leverage reduction, successful refinancing, improved product availability, strong neurosurgery performance, and several 2027 growth initiatives. However, these positives were balanced by the Cincinnati disruption, reduced revenue and EPS outlooks, Tissue Reconstruction weakness, gross-margin pressure, higher refinancing-related interest expense, and continued competitive and execution challenges. Overall sentiment was balanced, with a constructive long-term outlook but significant near-term headwinds.
View all DE:IL3 earnings summariesIL3 Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 12 | 4 | 6 |
| Technical Analysis | 3 | 4 | 3 |
| Moving Averages | 9 | 0 | 3 |
